Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Elotuzumab

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 8Empliciti

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Empliciti

    Elotuzumab

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Empliciti

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Elotuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 381

    2019 Revenue in Millions : 357

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Empliciti

    Elotuzumab

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Empliciti

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Elotuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 334

    2020 Revenue in Millions : 381

    Growth (%) : -12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Empliciti

    Elotuzumab

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Empliciti

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Elotuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 296

    2021 Revenue in Millions : 334

    Growth (%) : -11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Empliciti

    Elotuzumab

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Empliciti

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol-Myers Squibb

    Elotuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2015 Revenue in Millions : 0

    2014 Revenue in Millions : 3

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Empliciti

    Elotuzumab

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Empliciti

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Elotuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2017 Revenue in Millions : 231

    2016 Revenue in Millions : 150

    Growth (%) : 54

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Empliciti

    Elotuzumab

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Empliciti

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Elotuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2016 Revenue in Millions : 150

    2015 Revenue in Millions : 3

    Growth (%) : 4,900

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Empliciti

    Elotuzumab

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Empliciti

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb

    Elotuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 247

    2017 Revenue in Millions : 231

    Growth (%) : 7%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Empliciti

    Elotuzumab

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Empliciti

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Bristol Myers Squibb/Celgene

    Elotuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 357

    2018 Revenue in Millions : 247

    Growth (%) : 45

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF